From the Issue
Dasatinib Plus Chemo Approved by FDA for Treatment of Pediatric Ph+ ALL
Dasatinib, the first and only second-generation TKI approved for pediatric patients with newly diagnosed Ph+ ALL in combination with chemo, adds another important tool to a medical toolkit that had long been light on options.
A Discussion About the Field of Hematology/Oncology
HemOnc Times caught up with Pamela Crilley, DO, and Praneeth Baratam, MD, to get perspectives on the field from a seasoned hematologist/oncologist as well as one at the beginning of his career.
Read More Research Highlights
Are you looking for the latest hematology/oncology research? Check out additional highlights featuring the cutting-edge discoveries in the field.